KLP Kapitalforvaltning AS Makes New $97,000 Investment in SI-BONE, Inc. (NASDAQ:SIBN)

KLP Kapitalforvaltning AS acquired a new stake in SI-BONE, Inc. (NASDAQ:SIBN) during the 4th quarter, Holdings Channel reports. The institutional investor acquired 6,900 shares of the company’s stock, valued at approximately $97,000.

A number of other institutional investors have also modified their holdings of SIBN. FMR LLC raised its holdings in SI-BONE by 103.6% in the third quarter. FMR LLC now owns 2,354 shares of the company’s stock valued at $33,000 after buying an additional 1,198 shares during the period. Mainstream Capital Management LLC purchased a new position in shares of SI-BONE in the 4th quarter valued at $53,000. R Squared Ltd purchased a new position in shares of SI-BONE in the 4th quarter valued at $73,000. Walleye Capital LLC acquired a new position in shares of SI-BONE during the 3rd quarter valued at $144,000. Finally, Proficio Capital Partners LLC purchased a new stake in SI-BONE during the 4th quarter worth $155,000. Hedge funds and other institutional investors own 98.11% of the company’s stock.

SI-BONE Stock Down 4.8 %

Shares of SI-BONE stock opened at $13.25 on Friday. SI-BONE, Inc. has a 1-year low of $11.70 and a 1-year high of $19.16. The company has a market capitalization of $562.50 million, a PE ratio of -14.40 and a beta of 1.02. The company has a debt-to-equity ratio of 0.22, a current ratio of 8.25 and a quick ratio of 7.22. The business has a 50-day moving average of $15.74 and a 200-day moving average of $14.64.

SI-BONE (NASDAQ:SIBN) last issued its quarterly earnings results on Monday, February 24th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.05. SI-BONE had a negative return on equity of 22.51% and a negative net margin of 23.82%. The firm had revenue of $49.00 million during the quarter, compared to the consensus estimate of $48.87 million. As a group, equities analysts forecast that SI-BONE, Inc. will post -0.78 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Anthony J. Recupero sold 3,311 shares of SI-BONE stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $14.15, for a total value of $46,850.65. Following the completion of the transaction, the insider now directly owns 284,555 shares in the company, valued at approximately $4,026,453.25. This trade represents a 1.15 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Michael A. Pisetsky sold 3,128 shares of the company’s stock in a transaction that occurred on Wednesday, April 2nd. The shares were sold at an average price of $14.14, for a total value of $44,229.92. Following the sale, the senior vice president now owns 244,878 shares in the company, valued at $3,462,574.92. The trade was a 1.26 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 6,776 shares of company stock worth $96,644. Insiders own 3.90% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on SIBN shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $25.00 price objective on shares of SI-BONE in a research report on Tuesday, February 25th. Truist Financial reiterated a “buy” rating and issued a $22.00 target price (up previously from $18.00) on shares of SI-BONE in a research note on Tuesday, February 25th. Finally, Needham & Company LLC boosted their price target on SI-BONE from $20.00 to $24.00 and gave the stock a “buy” rating in a research report on Tuesday, February 25th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, SI-BONE has an average rating of “Buy” and a consensus price target of $24.40.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.